Patient CD34+ hematopoietic stem cell genome (CD34+ HSC genome)

The Patient CD34+ hematopoietic stem cell genome refers to the complete set of deoxyribonucleic acid (DNA) within autologous hematopoietic stem and progenitor cells (HSPCs) that express the CD34 surface marker (NIH: PMC3674466). These cells are characterized by their capacity for self-renewal and multilineage differentiation into erythrocytes, leukocytes, and platelets (StatPearls: NBK555974). In the field of regenerative medicine, this genome is the primary substrate for ex vivo gene therapies, where specific loci are targeted for modification to treat inherited hematologic disorders (FDA: Approved Cellular and Gene Therapy Products). For instance, CRISPR-Cas9 technology is used to disrupt the BCL11A erythroid-specific enhancer within this genome to induce fetal hemoglobin in patients with sickle cell disease (NEJM: 10.1056/NEJMoa2304825). Alternatively, lentiviral vectors are employed to integrate functional copies of genes, such as the beta-globin gene, directly into the host cell's DNA (Nature: 10.1038/s41586-020-2428-2). Because these modifications occur at the genomic level in stem cells, the therapeutic effects are intended to be permanent as the edited cells repopulate the patient's bone marrow. This target represents a paradigm shift from traditional pharmacology, focusing on the permanent alteration of the cellular blueprint rather than transient protein inhibition. Clinical success depends on the efficient collection of these cells and the precision of the genomic intervention to avoid deleterious off-target effects.

Other names

CD34+ HSPC genomeHematopoietic stem cell DNAAutologous CD34+ cell genomeHSC genome

Ex vivo genetic modification of autologous stem cells via gene addition (lentiviral transduction) or gene editing (CRISPR-Cas9) to correct or compensate for genetic mutations (FDA: 2023).